Harvard Bioscience (HBIO) reported second-quarter 2026 revenue of $22.7 million, up 11% from $20.5 million a year earlier. The company reported a GAAP net loss of $2.9 million, compared with a net loss of $2.3 million in the second quarter of 2025.
For the first six months of 2026, revenue was $43.5 million, compared with $42.2 million in the prior-year period. Harvard Bioscience raised its full-year 2026 revenue guidance to growth of 3% to 5% year over year.
- Second-quarter gross profit was $12.6 million, with gross margin of 55.6%.
- Second-quarter adjusted EBITDA was $1.7 million, compared with $1.5 million a year earlier.
- Six-month net loss was $6.3 million, compared with a net loss of $52.6 million in the prior-year period.
- Third-quarter 2026 revenue guidance is $21.0 million to $22.6 million.
- Full-year adjusted EBITDA growth guidance is 6% to 10%.
$HBIO Insider Trading Activity
$HBIO insiders have traded $HBIO stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $HBIO stock by insiders over the last 6 months:
- WILLIAM SNIDER has made 2 purchases buying 21,000 shares for an estimated $103,603 and 0 sales.
- STEPHEN J DENELSKY purchased 10,000 shares for an estimated $48,700
- JOHN D DUKE (Chief Executive Officer) purchased 5,000 shares for an estimated $25,050
- MARK T FROST (Chief Financial Officer) purchased 5,000 shares for an estimated $25,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$HBIO Hedge Fund Activity
We have seen 8 institutional investors add shares of $HBIO stock to their portfolio, and 40 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ACADIAN ASSET MANAGEMENT LLC added 179,614 shares (+inf%) to their portfolio in Q1 2026, for an estimated $874,720
- NANO CAP NEW MILLENNIUM GROWTH FUND L P added 57,500 shares (+95.8%) to their portfolio in Q1 2026, for an estimated $280,025
- PORTOLAN CAPITAL MANAGEMENT, LLC removed 40,965 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $199,499
- JANE STREET GROUP, LLC removed 17,686 shares (-42.6%) from their portfolio in Q1 2026, for an estimated $86,130
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 13,987 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $68,116
- CORSAIR CAPITAL MANAGEMENT, L.P. added 13,941 shares (+12.6%) to their portfolio in Q1 2026, for an estimated $67,892
- ASSENAGON ASSET MANAGEMENT S.A. removed 13,922 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $67,800
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
